CP and Wilson disease: However, monitoring treatment effects in WD is challenging and is based on several tools, including calculation of non-ceruloplasmin bound copper (cNCC), direct measurement of non-ceruloplasmin bound copper (CuEXC), and 24-hour urinary copper excretion (24 H-UCE) [12–14].